• Alexandre Vivien, Julien Ancel, Sophie Godet, Sandra Dury, Jeanne-Marie Perotin, Gaetan Deslee, and Claire Launois.
• Department of Respiratory Diseases, Reims University Hospital, Reims, France.
• Medicine (Baltimore). 2023 Jan 13; 102 (2): e32473e32473.

RationalePomalidomide is an immunomodulatory imide drug used in multiple myeloma and in Kaposi sarcoma.Patient ConcernsA 72-years-old male, treated for multiple myeloma with dexamethasone, pomalidomide and daratumumab, presented dyspnea, hypoxemia, biological inflammatory syndrome, ground glass opacities on computed tomography scan (CT-scan) and lymphocytic and eosinophilic alveolitis, with no specific cytologic or microbiological findings, 2 months after pomalidomide initiation.Intervention And OutcomeAntibiotics were started after bronchoscopy. No improvement was noted in dyspnea and biological inflammatory syndrome after 5 days of treatment. Pomalidomide was then discontinued, with continuation of Daratumumab-Dexamethasone, resulting in a rapid recovery of symptoms and CT-scan anomalies. No recurrence of dyspnea was observed during the 15 months of follow-up.DiagnosesPomalidomide-induced lung injury.LessonsPomalidomide-induced lung injury is a rare and serious adverse event that can occur early after Pomalidomide introduction. As pomalidomide use is increasing, the identification of drug toxicity as a possible cause of lung injury appears important. We report a rapid recovery of symptoms and CT-scan anomalies after pomalidomide discontinuation.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

16 keywords...

hide…